INTRODUCTION
============

Postoperative venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is a serious and potentially life-threatening complication and an important safety issue in acute care hospitals ([@B1]). Among major surgical procedures, hip and knee replacement arthroplasty (HKRA) carries the greatest risk of VTE. In the absence of prophylactic therapy, the incidence of postoperative VTE is particularly high after lower extremity arthroplasty. The incidence of imaging-confirmed asymptomatic DVT was known to vary from 42% to 57% after hip arthroplasty, and from 41% to 85% after knee arthroplasty. The incidence of PE varies from 0.9% to 28% after hip arthroplasty, and from 1.5% to 10% after knee arthroplasty ([@B2]). Clinically significant symptomatic VTE has been reported to be less common ([@B2][@B3]).

It has been suggested that there is a substantially lower incidence of VTE after HKRA in Asian populations compared with Western populations ([@B4][@B5][@B6]). However, in recent multicenter prospective studies performed in Asia, incidences of VTE after major orthopedic surgery including arthroplasty were comparable to those in Western populations ([@B7][@B8][@B9]). Moreover, there are few reports on the incidence of clinically-relevant symptomatic VTE after HKRA in East Asian patients ([@B5][@B6]). To determine to use thromboprophylactic agents routinely after HKRA, a study of symptomatic VTE in a large number of patients is necessary. There is marked discrepancy among reference studies. Major confounding factors might be various diagnostic modalities with different sensitivity, monitoring duration, lack of information on the use of mechanical device, study design, and surgeon vigilance.

In this study, we evaluated nationwide data regarding the incidence of VTE after HKRA in Korea using the administrative claims database of the Health Insurance Review and Assessment Service (HIRA), which comprises fully adjudicated medical and pharmacy claims for 50 million beneficiaries in Korea. Every clinic, hospital, and pharmacy in Korea is obliged to submit patient data regarding healthcare services and medical costs to the HIRA for reimbursement ([@B10]). Therefore, almost all clinically-relevant VTE events can be identified by analyzing the HIRA database.

The aim of this study was to examine the incidence and trends of clinically-relevant VTE including PE among patients who had undergone HKRA in Korea.

MATERIALS AND METHODS
=====================

Data source
-----------

We analyzed the Korean National Health Insurance (NHI) claims database from HIRA, which examines the accuracy of claims for NHI and National Medical Aid (NMA) programs. The NHI database includes the entire Korean population (approximately 96.6% of the entire 48.6 million population as well as registered foreign-nationals) as a compulsory insurance system, with exceptions for cases applicable to the NMA program covering the remaining 3.4% of the population and foreign military personnel. The claims data covered by NMA program are also reviewed by HIRA. Thus, nearly all information about patients is available from the HIRA database. Information in the HIRA database includes a unique identification number for each patient, age, sex, and all medical services rendered, along with the diagnostic code (based on the International Classification of Diseases, ICD, Tenth Edition), all prescription medications dispensed (based on code for drug ingredient), and procedure history (based on electronic data interchange \[EDI\] code). Additional information includes hospital type where the surgery was performed and the duration of hospitalization.

Study population and baseline characteristics
---------------------------------------------

We identified 22,127 patients who underwent hip replacement arthroplasty (HRA) and 52,882 patients who underwent knee replacement arthroplasty (KRA) at 882 hospitals nationwide between January 1 and December 31, 2010. The date of index surgery was defined as the initiation date of hospitalization for HKRA on claims registry data. HRA procedure codes included N0715 for primary bipolar hip hemiarthroplasty, N0711 for primary total hip arthroplasty, N1715 and N1725 for revision partial hip arthroplasty (acetabular or stem revision only), and N1711 and N1721 for revision total hip arthroplasty. KRA procedure codes included N2712 (primary unicompartmental knee arthroplasty), N2072 (primary total knee arthroplasty), N4712 and N4722 (revision partial knee arthroplasty), N3712 and N3722 (revision total knee arthroplasty). Patients over 100 yr of age and those who received HRA and KRA at the same hospitalization were excluded. The use of pharmacological VTE prophylaxis such as aspirin, fondaparinux, rivaroxaban, and low molecular weight heparin (LMWH) was identified for each patient. 37.3% of 22,127 HRA patients (n=8,259) and 48.4% of 52,882 KRA patients (n=25,577) had received chemoprophylaxis. The results of the patients in chemoprophylaxis group were assessed and compared with those of 13,868 HRA patients (62.7%) and 27,305 KRA patients (51.6%) who had not received chemoprophylaxis ([Fig. 1](#F1){ref-type="fig"}). All clinically relevant VTE during hospitalization and 90 days after HKRA were recorded using the ICD-10 code classification (180, 182 for DVT; 126 for PE). Baseline characteristics and potential risk factors including patient age, sex, comorbidities, and surgery characteristics were summarized using descriptive statistics such as proportion, mean, and standard deviation. Items for baseline characteristics and preoperative morbidities of the patients were listed with reference to the Korean Guideline for the Prevention of VTE in 2010, Guideline for the Prophylaxis of Venous Thromboembolism in Hip Surgery Patients in 2011, American Academy of Orthopaedic Surgery (AAOS) guideline in 2011, 9th edition of the American College of Chest Physicians (ACCP) evidence-based clinical practice guideline, NICE guideline in 2010, and the literature. All listed items were reviewed by statisticians and clinical experts.

Statistical analyses
--------------------

Hospital type was categorized into four groups (tertiary hospital, general hospital, hospital, and clinic). Independent *t*-test was used for comparison of continuous variables, and chi-square test or Fisher\'s exact test was used for categorical variables. The chi-square test of independence was used to evaluate the difference in the incidence among arthroplasty type; and the cumulative incidence of VTE was analyzed with the Kaplan-Meier method. Multivariate logistic regression was used to calculate the adjusted odds ratio. Chi-square test was performed to compare the incidence between patients with and without comorbidities. A *P* value \<0.05 was considered statistically significant. SAS® statistical software version 9.2 (SAS Institute, Cary, NC, USA) was used for data management and statistical analyses.

Ethics statement
----------------

This study protocol was reviewed and approved by the institutional review board of the National Evidence-based Healthcare Collaborating Agency (NECAIRB 12-004-1) and Seoul National University Hospital (E-1304-066-482). The board waived informed consent from involved subjects.

RESULTS
=======

The percent of female patients with knee replacement was higher than that with hip replacement. The age of most patients with hip replacement was evenly distributed between 45 and 84 yr, while more than half of the patients with knee replacement (52.1%) were between 65- and 74-yr-of-age. Hypertension showed the highest prevalence (57.1% to 72.5%) among past medical morbidities. Diabetes, coronary artery stenosis, malignancy and stroke also showed high prevalence. Most hip and knee replacements were performed in general and secondary level hospitals, whereas more hip replacements were performed in tertiary general hospitals (35.0%) than hospitals (22.8%) in the group receiving chemoprophylaxis. More than half of HRAs were primary bipolar hip hemiarthroplasty (57.2%) and one-third was primary total hip arthroplasty (32.3%). Regarding KRA, unilateral primary total knee arthroplasty comprised 54.2% of surgeries and bilateral total knee arthroplasty 39.3%. It was unknown whether the bilateral surgeries were simultaneous or staged. Regional anesthesia was used in 87.9% and packed red blood cells were transfused in 83.1%. In 96.1% of HKRA cases, platelets were not transfused. The mean duration of anesthesia was 2.9 hr for HRA and 2.8 hr for KRA. Gender ratio, age, VTE history, diabetes, stroke, hypertension, coronary artery stenosis, arrhythmia, anticoagulation therapy, surgical characteristics, and RBC transfusion differed between the group with chemoprophylaxis and the group without chemoprophylaxis among baseline characteristics ([Table 1](#T1){ref-type="table"}).

The overall incidence of VTE, DVT, and PE during the 90 days after HRA was 3.9% (853 of 22,127), 2.7% (597 of 22,127), and 1.5% (327 of 22,127), respectively. During hospitalization, 70.3% of VTE, 69.7% of DVT, 66.7% of PE developed. After KRA, the incidence of VTE, DVT, and PE during 90 days was 3.8% (1,990 of 52,882), 3.2% (1,699 of 52,882), and 0.7% (355 of 52,882). During hospitalization, 77.7% of VTE, 79.5% of DVT, and 63.7% of PE developed ([Table 2](#T2){ref-type="table"}).

Postoperative VTE and PE occurred the most frequently after primary hip hemiarthroplasty; and the incidence of DVT was the highest after revision hip arthroplasty. PE incidence after hemiarthroplasty was more than twice that of primary total or revision hip arthroplasty. VTE incidence after KRA was similar among unilateral primary total knee arthroplasty, bilateral primary total knee arthroplasty, and revision knee arthroplasty. DVT occurred the most frequently after unilateral primary total knee arthroplasty; and PE incidence was the highest after revision knee arthroplasty. VTE, DVT and PE incidence of primary unicompartmental knee arthroplasty was the lowest among various types of knee surgery ([Table 2](#T2){ref-type="table"}).

Chemoprophylaxis was used for VTE prevention more frequently in KRA (48.4%) than in HRA (37.3%). The incidence of VTE of the group with chemoprophylaxis was compared with that of the group without chemoprophylaxis. VTE, DVT and PE incidence was significantly higher in the group with chemoprophylaxis. Every incidence by the type of surgery was higher in chemoprophylaxis group except for PE incidence after the revision knee arthroplasty ([Table 3](#T3){ref-type="table"}).

The incidence of VTE, DVT, and PE after HKRA was significantly higher in patients who had previous VTE history, chronic heart failure, arrhythmia, and atrial fibrillation than those in patients who did not have those risk factors ([Tables 4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}). Previous VTE history was the strongest risk factor of VTE and PE for both HRA (OR, 10.8 and 9.7) and KRA (OR, 8.5 and 8.6).

DISCUSSION
==========

The incidence of clinically relevant VTE, DVT and PE following HKRA was 3.8%, 3.1%, and 0.9%, respectively in the present study. More than half of the VTEs occurred during hospitalization. DVT was found more frequently after KRA whereas the incidence of PE after HRA was higher than that after KRA. Chemoprophylaxis was done for VTE prevention more frequently in KRA than HRA. The difference between prophylaxis and non-prophylaxis group makes it difficult to draw firm conclusion on the matter of routinely using chemoprophylaxis. Incidence of postoperative VTE varies extensively in the literature, not only by ethnic differences and the characteristics of the population, but also by the diagnostic modalities such as venography, CT scan, or duplex ultrasonography, presence of symptoms, the location of the thrombosis, the postoperative monitoring duration, and the use of mechanical preventive devices. The results may have been biased similarly in this study.

With all these limitations considered, however, the most important finding was that the incidence of VTE, DVT and PE was not low compared to the incidence in other Asian or Western population studies. This interpretation is mainly based upon the high incidence of VTE in the group of patients who received chemoprophylaxis. The incidence of VTE and DVT that was 7.0%, 5.1% for HRA and 6.2%, 5.4% for KRA, and the incidence of PE that was 2.5% and 1.0% was comparable to those in the high incidence population in the literature. VTE incidence after HKRA decreased dramatically in the past two to three decades and several recent studies showed 0.5%-4.5% PE rate after HRA and 0.0\~1.0% after KRA without chemoprophylaxis ([@B11]). Even lower rates were shown in a systematic review where symptomatic VTE and PE were 0.5%-1.1% and 0.1%-0.3% respectively with chemoprophylaxis ([@B1]). A Western population-based registry data has shown clinically significant VTE as 2.3% after total hip arthroplasty and 1.8% after total knee arthroplasty ([@B12]). A meta-analysis of Asian population studies revealed the pooled rate of proximal DVT as 8.9% using venography and 5.9% by ultrasonography ([@B13]). Symptomatic PE was 0.6% in the same study. Overall VTE in this study included events diagnosed with various modalities although they lacked specific information for individual patient. As indicated in other studies with similar methodology, HIRA database has also possibilities that clinicians had diagnosed the patients as having VTE by clinical suspicion only, not by using objective diagnostic methods ([@B14]).

Along with the possible overestimation of the VTE incidence, there is also possibility of underestimation in this study as there was no way to identify the number of undiagnosed VTE in the population. The observed VTE incidence in the group without prophylaxis was comparable with the relatively low incidence from several Asian studies. A meta-analysis showed a pooled incidence rate as low as 5.8% for proximal DVT diagnosed by venography and 1.9% for symptomatic DVT after KRA in Asian patients which coincides with the results of non-prophylaxis group in the present study ([@B6]). Recent Asian studies showed that the incidence of all DVT was 8%-49% in patients not receiving chemoprophylaxis ([@B15],[@B16],[@B17]). The relatively low incidence of VTE in Asian studies has prompted the disagreement on routine chemoprophylaxis after HKRA ([@B18][@B19][@B20]). The low incidence of VTE in Asians is known to be attributed to the low incidence of obesity and hyperlipidemia as well as the scarcity of some genetic factors ([@B4][@B19]). The current practice includes early postoperative mobilization, the use of stockings and pneumatic compression pumps which may help prevent VTE ([@B21][@B22]).

Given that the rate of symptomatic PE and sudden death are the ultimate targets of VTE prophylaxis and whether an ethnic difference in the incidence of PE exists is still inconclusive, it is vital to explore the incidence of these parameters. The incidence of fatal PE in Western studies appears to have decreased dramatically when compared to the past records due to early mobilization. In one study by Charnley, the PE was 7.8%, despite various approaches of chemical prophylaxis ([@B23]). Reported estimates of symptomatic PE in a more recent meta-analysis with Western populations were 0%-1.5% after HRA and 0%-1.3% after KRA with or without chemoprophylaxis ([@B24][@B25]). Data of the Scottish Arthroplasty Registry revealed an incidence of fatal PE during 90 days was 0.2% after HRA and 0.2% after KRA ([@B12]). Several studies conducted in the United Kingdom with over 1,000 patients reported rates of fatal PE varying from 0.1%-0.4% without chemical prophylaxis after HKRA ([@B26][@B27]). For Asian subjects, two large-scale trials reported rates of symptomatic PE as 0.5% and 0.4% ([@B7][@B8]). Two recent meta-analyses showed that the rate of symptomatic PE was 0.6% (0%-2.5%) and 0.01% (0.01%-2.9%) ([@B6][@B13]). The observed PE incidence ranging from 0.0 to 3.7% in the present study corresponded to approximately one third that of VTE and this incidence was not low regardless of chemoprophylaxis. The PE incidence in the patients with prophylaxis was rather comparable to that reported in numerous earlier Western studies, whether they were symptomatic or not.

It is notable that overall VTE incidence during 90 days was lower after KRA than after HRA. Bipolar hip hemiarthroplasty and revision surgery of the knee carried a higher risk of VTE and PE occurrence than total hip replacement surgery, revision hip replacement arthroplasty and other type of knee replacement surgeries. Higher incidence of overall VTE after KRA than HRA has been demonstrated in many Western and Asian populations studies ([@B1][@B7][@B8][@B28]). High incidence of VTE and PE in bipolar hip hemiarthroplasty is explained in part by the fact that it corresponds to the surgery for hip fracture. Hip fracture surgery has shown greater risk for VTE than THA ([@B7][@B8]). We also should note that the gap between HRA and KRA became smaller or the rates were reversed concerning proximal or symptomatic DVT or PE in those studies ([@B12][@B13]). It may be due to the size and location of thrombi and postoperative mobilization. The size of their thrombi were smaller and less occlusive after KRA, which caused fewer symptoms than HRA ([@B29]).

Another finding was that 20% to 35% of VTE occurred after discharge from the hospital. It has already been proposed that the prophylaxis must be continued after discharge as the risk persists. This vigilance is heightened if the hospitalization is rather short-term as in most western countries where the DVT prophylaxis is mainly post-discharge procedure. The exact duration and selection criteria of at-risk patients for post-discharge chemoprophylaxis, however, is uncertain. The current ACCP thromboprophylaxis guideline recommends extension of prophylactic period for up to 35 days ([@B30]). Duration of chemoprophylaxis should be determined considering the cumulative incidence of postoperative VTE that changes with prophylaxis. There is general agreement that the risk of VTE is the highest soon after HKRA during hospitalization and the incidence of asymptomatic DVT decreases as the duration of postoperative prophylaxis increases ([@B31]). We should also consider the duration of hospitalization in Asian studies is generally longer than that reported in Western studies. In an Asian multicenter study including 835 patients, no symptomatic VTE occurrence was evident between hospital discharge and 3 months after surgical procedure, in which study the duration of hospital stay was 12-15 days ([@B8]). In the current study, the mean duration of hospital stay was 19.2 days for primary total hip replacement arthroplasty and 20.2 days for total knee replacement arthroplasty including bilateral cases.

Previous history of VTE, chronic heart failure, arrhythmia, and atrial fibrillation were risk factors identified in this study. They are well known factors from other studies ([@B32]). The odds ratio of the incidence of VTE for patients with previous VTE history in this study was 10.8 after HRA and 8.5 for KRA patients when compared to subjects without VTE history. This finding justifies the routine use of chemical prophylaxis for those selected patients. However, the individualized therapy that depends on risk factors has not yet been endorsed in western guidelines because the risk of orthopedic replacement surgery far outweighs patient-specific factors. A study conducted before 1990 reported that \'hospitalization with recent surgery\' resulted in an odds ratio of 22 ([@B33]). The current clinical practice guidelines by the Korean Society of Thrombus and Hemostasis in 2014 stratified the joint replacement surgery as moderate risk group with weak recommendation of prophylaxis whereas they stratified the joint replacement surgery with previous VTE as high risk group ([@B34]).

This study has several limitations and weaknesses. The inherent limitation was that the evaluation of data relied solely on the EDI code input by the individual hospital; and the integrity of the information in the registry may vary depending on each hospital. The integrity of the data had been tested by correlating the authentic data in individual hospital and the input information, but the correlation was not possible. Also, only the items to be reimbursed by the insurance were involved, which meant that mechanical prophylaxis including pneumatic pumps and stockings was not included as they were not reimbursed by the insurance coverage. Subsequent over- or under-estimation of VTE incidence due to various factors is the serious limitation of this study. The data did not include the exact date and time of prophylaxis initiation, duration of prophylactic treatment, or the date of surgery. The timing of prophylactic treatment initiation can affect the efficacy of the anticoagulation along with the incidence of bleeding after hip surgery ([@B35]). Body mass index was not estimated as weight or height had not been recorded in the registry. Symptom severity of each patient was evaluated by the surgeon of each hospital and the criteria for positive symptomatic DVT or PE was not standardized.

In conclusion, this nationwide database enables an estimation of the incidence of total venous thromboembolic disease occurring in Korea after HKRA. The incidence of VTEs in this retrospective review was not low compared with the results of the studies targeting other Asian and Caucasian populations. It may warrant routine prevention including employment of chemoprophylaxis. However, the inconsistency and limitation of the data indicates true incidence may not have been revealed regardless of potential risks. A nationwide prospective investigation involving a large-scale controlled trial is required to affirm this reviewed data and to develop the necessary recommendations.
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![Selection process and flowchart of study population. A flowchart shows the selection process of study population. A total of 22,127 patients who underwent hip replacement arthroplasty (HRA) and 52,882 patients who underwent knee replacement arthroplasty (KRA) at 882 hospitals nationwide were finally enrolled in the analysis between January 1 and December 31, 2010. Multiple hospitalizations were defined as one episode of hospitalizaton if the interval between the two successive hospitalizations was less than 2 days. Index procedure: the first replacement arthroplasty during the study period. Index date: the first date of hospitalization during which the index replacement arthroplasty was performed.](jkms-31-80-g001){#F1}

###### Baseline characteristics of patients with hip and knee replacement

![](jkms-31-80-i001)

  Parameters                                                  Patients with knee replacement   Patients with knee replacement                                                   
  ----------------------------------------------------------- -------------------------------- -------------------------------- --------------- --------------- --------------- ------------
  Gender                                                                                                                        0.001                                           0.001
   Male                                                       5,445 (39.3)                     3,052 (37.0)                     3,553 (13.0)    2,927 (11.4)                    
   Female                                                     8,423 (60.7)                     5,207 (63.0)                     23,752 (87.0)   22,650 (88.6)                   
  Age (yr)^‡^                                                                                                                                                                   
   Mean ± SD                                                  68.6±15.2                        69.6±14.2                        \<0.001         68.5±7.7        68.6±7.0        0.333
   ≤ 44                                                       1,145 (8.3)                      547 (6.6)                        \<0.001^†^      141 (0.5)       36 (0.1)        \<0.001^†^
   45 ≤ age ≤ 64                                              3,433 (24.8)                     1,900 (23.0)                                     7,070 (25.9)    6,595 (25.8)    
   65 ≤ age ≤ 74                                              3,456 (24.9)                     2,254 (27.3)                                     14,222 (52.1)   13,860 (54.2)   
   75 ≤ age ≤ 84                                              4,077 (29.4)                     2,572 (31.1)                                     5,700 (20.9)    4,939 (19.3)    
   ≥ 85                                                       1,757 (12.7)                     986 (11.9)                                       172 (0.6)       147 (0.6)       
  Past medical history                                                                                                                                                          
   Venous thromboembolic event (\<3 yr)                       317 (2.3)                        308 (3.7)                        \< 0.001        644 (2.4)       759 (3.0)       \< 0.001
   Surgical site infection (\<3 yr)                           536 (3.9)                        328 (4.0)                        0.693           487 (1.8)       424 (1.7)       0.267
   Diabetes (\<3 yr)                                          5,600 (40.4)                     3,622 (43.9)                     \< 0.001        12,172 (44.6)   11,817 (46.2)   \< 0.001
   Stroke (\<3 yr)                                            2,534 (18.3)                     1,746 (21.1)                     \< 0.001        3,449 (12.6)    3,216 (12.6)    0.842
   Renal disease (\<3 yr)                                     800 (5.8)                        567 (6.9)                        0.001           1,305 (4.8)     1,253 (4.9)     0.522
   Hypertension (\<3 yr)                                      7,912 (57.1)                     5,322 (64.4)                     \< 0.001        18,691 (68.5)   18,551 (72.5)   \< 0.001
   Coronary artery stenosis ( \< 3 yr)                        2,819 (20.3)                     2,216 (26.8)                     \<0.001         6,545 (24.0)    6,683 (26.1)    \< 0.001
   Chronic heart failure, congestive heart failure (\<3 yr)   1,012 (7.3)                      794 (9.6)                        \< 0.001        2,003 (7.3)     1,819 (7.1)     0.321
   Arrhythmia (\<3 yr)                                        828 (6.0)                        629 (7.6)                        \< 0.001        1,862 (6.8)     1,900 (7.4)     0.007
   Atrial fibrillation ( \< 3 yr)                             455 (3.3)                        486 (5.9)                        \< 0.001        736 (2.7)       750 (2.9)       0.100
   Malignancy (≤3 yr)                                         1,616 (11.7)                     970 (11.7)                       0.837           2,230 (8.2)     2,043 (8.0)     0.450
   Varicose vein (\<3 yr)                                     127 (0.9)                        99 (1.2)                         0.043           708 (2.6)       724 (2.8)       0.092
   Hormone therapy (≤1 yr)                                    368 (2.7)                        247 (3.0)                        0.140           892 (3.3)       857 (3.4)       0.590
   Anticoagulation therapy (\<6 mo)                           751 (5.4)                        718 (8.7)                        \< 0.001        1,109 (4.1)     1,386 (5.4)     \< 0.001
  Surgical characteristics                                                                                                                                                      
   Hospital pattern (level of reference)                                                                                        \<0.001                                         \<0.001
    Tertiary general hospital                                 2,569 (18.5)                     2,890 (35.0)                     3,259 (11.9)    3,320 (13.0)                    
    General hospital                                          6,209 (44.8)                     3,444 (41.7)                     7,176 (26.3)    6,382 (25.0)                    
    Hospital                                                  4,798 (34.6)                     1,887 (22.8)                     15,336 (56.2)   15,407 (60.2)                   
    Clinic                                                    292 (2.1)                        38 (0.5)                         1,534 (5.6)     468 (1.8)                       
   Type of surgery                                                                                                              \<0.001^†^                                      \<0.001^†^
    HRA: Primary bipolar hip hemiarthroplasty                 8,256 (59.5)                     4,399 (53.3)                                                                     
    HRA: Primary total hip arthroplasty                       4,248 (30.6)                     2,904 (35.2)                                                                     
    HRA: Revision partial hip arthroplasty                    508 (3.7)                        364 (4.4)                                                                        
    HRA: Revision total hip arthroplasty                      856 (6.2)                        592 (7.2)                                                                        
    KRA: Primary unicompartmental knee arthroplasty                                                                             735 (2.7)       580 (2.3)                       
    KRA: Unilateral primary total knee arthroplasty                                                                             15,784 (57.8)   12,869 (50.3)                   
    KRA: Bilateral primary total knee arthroplasty                                                                              9,600 (35.2)    11,169 (43.7)                   
    KRA: Revision partial knee arthroplasty                                                                                     364 (1.3)       334 (1.3)                       
    KRA: Revision total knee arthroplasty                                                                                       822 (3.0)       625 (2.4)                       
   Anesthesia^§^                                                                                                                \<0.001^†^                                      \<0.001^†^
    Regional anesthesia                                       11,209 (80.8)                    6,450 (78.1)                     24,512 (89.8)   23,744 (92.8)                   
    General anesthesia                                        2,659 (19.2)                     1,809 (21.9)                     2,793 (10.2)    1,833 (7.2)                     
   RBC transfusion (unit)                                                                                                                                                       
    Mean±SD                                                   3.5±2.8                          4.0±3.1                          \<0.001         3.5±2.1         4.3±2.7         \<0.001
    0                                                         2,198 (15.8)                     1,205 (14.6)                     \<0.001^†^      5,498 (20.1)    3,782 (14.8)    \<0.001^†^
    0\<RBC≤3                                                  7,520 (54.2)                     3,792 (45.9)                                     12,948 (47.4)   9,918 (38.8)    
    \>3                                                       4,150 (29.9)                     3,262 (39.5)                                     8,859 (32.4)    11,877 (46.4)   
   Platelet transfusion (unit)                                                                                                                                                  
    Mean±SD                                                   8.7±13.7                         7.4±11.2                         0.728           6.3±8.9         6.1±9.7         \<0.001
    0                                                         12,802 (92.3)                    7,535 (91.2)                     \<0.001^†^      26,612 (97.5)   25,110 (98.2)   \<0.001^†^
    0\<Platelet concentrate≤3                                 521 (3.8)                        341 (4.1)                                        389 (1.4)       263 (1.0)       
    3\<Platelet concentrate≤10                                293 (2.1)                        246 (3.0)                                        190 (0.7)       141 (0.6)       
    \>10                                                      252 (1.8)                        137 (1.7)                                        114 (0.4)       63 (0.2)        
   Duration of anesthesia (hr)^∥^                                                                                                                                               
    Mean±SD                                                   2.9±2.0                          3.0±2.1                          0.242           2.9±1.7         2.7±1.7         \<0.001
    \<2.5                                                     2,188 (15.8)                     1,223 (14.8)                     0.005^†^        3,124 (11.4)    3,994 (15.6)    \<0.001^†^
    2.5≤duration\<4                                           6,845 (49.4)                     4,262 (51.6)                                     9,843 (36.0)    7,912 (30.9)    
    ≥4                                                        4,810 (34.7)                     2,767 (33.5)                                     14,044 (51.4)   13,660 (53.4)   

^†^Independent *t*-test for continuous variables; ^†^Chi-square test or Fisher\'s exact test for categorical variables; ^‡^Age at Index date of arthroplasty; ^§^Defined as general anesthesia if inhalant was used; ^∥^No record of anesthesia duration : hip (n=32), Knee (n=305).

###### Incidence of VTE in hospitalization and within 90 days after hip and knee replacement
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  Type of surgery                                          Within 90 days after surgery   In hospitalization                                                                                                                  
  -------------------------------------------------------- ------------------------------ -------------------- -------------- --------- ------------ --------- -------------- --------- -------------- --------- ------------ ---------
  Hip (n=22,127)                                           853 (3.9%)                                          597 (2.7%)               327 (1.5%)             600 (2.7%)               416(1.9%)                218 (1.0%)   
   Primary hip hemiarthroplasty (n=12,655)                 572 (4.5%)                     \<0.001              358 (2.8%)     0.040     266 (2.1%)   \<0.001   381 (3.0%)     0.002     232 (1.8%)     0.028     175 (1.4%)   \<0.001
   Primary total hip arthroplasty (n=7,152)                203 (2.8%)                                          173 (2.4%)               42 (0.6%)              157 (2.2%)               132 (1.8%)               30 (0.4%)    
   Revision hip arthroplasty (n=1,448)                     58 (4.0%)                                           51 (3.5%)                12 (0.8%)              47 (3.2%)                41 (2.8%)                8 (0.6%)     
  Knee (n=52,882)                                          1,990 (3.8%)                                        1,699 (3.2%)             355 (0.7%)             1547 (2.9%)              1,351(2.6%)              226 (0.4%)   
   Unilateral primary total knee arthroplasty (n=28,653)   1,119 (3.9%)                   \<0.001              966 (3.4%)     \<0.001   186 (0.6%)   0.097     867 (3.0%)     \<0.001   769 (2.7%)     \<0.001   114 (0.4%)   0.293
   Bilateral primary total knee arthroplasty (n=20,769)    785 (3.8%)                                          663 (3.2%)               149 (0.7%)             615 (3.0%)               528 (2.5%)               100 (0.5%)   
   Primary unicompartmental knee arthroplasty (n=1,315)    14 (1.1%)                                           11 (0.8%)                4 (0.3%)               11 (0.8%)                8 (0.6%)                 3 (0.2%)     
   Revision knee arthroplasty (n=1,447)                    57 (3.9%)                                           45 (3.1%)                15 (1.0%)              42 (2.9%)                35 (2.4%)                8 (0.6%)     
  Overall (n=75,009)                                       2,843 (3.8%)                                        2,296 (3.1%)             682 (0.9%)             2,147 (2.9%)             1,767 (2.4%)             444 (0.6%)   

^\*^Chi-square homogeneous test for comparing the incidence among types of arthroplasties within the category of hip or knee. VTE, Venous thromboembolism; DVT, Deep vein thrombosis; PE, Pulmonary embolism.

###### Comparison of the VTE incidence according to chemoprophylaxis use after hip and knee replacement

![](jkms-31-80-i003)

  Type of surgery                               VTE          DVT            PE                                                                           
  --------------------------------------------- ------------ -------------- ---------- ------------- -------------- ---------- ------------ ------------ ----------
  Hip (n = 22,127)                              274 (2.0%)   579 (7.0%)     \< 0.001   177 (1.35%)   420 (5.1%)     \< 0.001   121 (0.9%)   206 (2.5%)   \< 0.001
   Primary hip hemiarthroplasty                 198 (2.4%)   374 (8.5%)     \< 0.001   116 (1.4%)    242 (5.5%)     \< 0.001   102 (1.2%)   164 (3.7%)   \< 0.001
   Primary total hip arthroplasty               58 (1.4%)    145 (5.0%)     \< 0.001   46 (1.1%)     127 (4.4%)     \< 0.001   15 (0.4%)    27 (0.9%)    0.002
   Revision total hip arthroplasty              13 (1.5%)    45 (7.6%)      \< 0.001   11 (1.3%)     40 (6.8%)      \< 0.001   3 (0.4%)     9 (1.5%)     0.016
  Knee (n = 52,882)                             406 (1.5%)   1,584 (6.2%)   \< 0.001   326 (1.2%)    1,373 (5.4%)   \< 0.001   103 (0.4%)   252 (1.0%)   \< 0.001
   Unilateral primary total knee arthroplasty   250 (1.6%)   869 (6.8%)     \< 0.001   201 (1.3%)    765 (5.9%)     \< 0.001   58 (0.4%)    128 (1.0%)   \< 0.001
   Bilateral primary total knee arthroplasty    132 (1.4%)   653 (5.8%)     \< 0.001   107 (1.1%)    556 (5.0%)     \< 0.001   36 (0.4%)    113 (1.0%)   \< 0.001
   Primary unicompartmental knee arthroplasty   2 (0.3%)     12 (2.1%)      0.002^†^   2 (0.3%)      9 (1.6%)       0.014^†^   0 (0.0%)     4 (0.7%)     0.038^†^
   Revision knee arthroplasty                   20 (2.4%)    37 (5.9%)      \< 0.001   14 (1.7%)     31 (5.0%)      \< 0.001   9 (1.1%)     6 (1.0%)     0.802
  Overall (n = 75,009)                          680 (1.7%)   2,163 (6.4%)   \<0.001    503 (1.2%)    1,793 (5.3%)   \<0.001    224 (0.5%)   458 (1.4%)   \<0.001

^\*^Chi-square homogeneous test for comparing the incidence between chemoprophylaxis (-) group and chemoprophylaxis (+) group; ^†^Fisher\' exact test. VTE, Venous thromboembolism; DVT, Deep vein thrombosis; PE, Pulmonary embolism.

###### Incidence of VTE after hip replacement in patients with significant risk factors

![](jkms-31-80-i004)

  Risk factors            VTE          DVT               PE                                                                               
  ----------------------- ------------ ----------------- ---------- ----------- ---------------- ----------- ----------- ---------------- ----------
  VTE history                                                                                                                             
   Yes (n = 317)          121 (19.4)   10.8 (8.4-13.8)   \< 0.001   84 (13.4)   9.2 (6.9-12.0)   \< 0.001    53 (8.5)    9.7 (6.9-13.5)   \< 0.001
   No (n = 13,551)        732 (3.4)                                 513 (2.4)                    274 (1.3)                                
  Chronic heart failure                                                                                                                   
   Yes (n = 1,012)        114 (6.3)    2.1 (1.7-2.6)     \< 0.001   63 (3.5)    1.5 (1.2-2.0)    0.002       58 (3.2)    2.8 (2.1-3.8)    \< 0.001
   No (n = 12,856)        739 (3.6)                                 534 (2.6)                                269 (1.3)                    
  Arrhythmia                                                                                                                              
   Yes (n = 828)          84 (5.8)     1.8 (1.4-2.2)     \< 0.001   56 (3.8)    1.7 (1.2-2.2)    \< 0.001    38 (2.6)    2.1 (1.5-3.0)    \< 0.001
   No (n = 13,040)        769 (3.7)                                 541 (2.6)                                289 (1.4)                    
  Atrial fibllation                                                                                                                       
   Yes (n = 455)          78 (8.3)     3.4 (2.6-4.4)     \< 0.001   46 (4.9)    2.6 (1.9-3.6)    \< 0.001    42 (4.5)    4.7 (3.3-6.6)    \< 0.001
   No (n = 13,413)        775 (3.7)                                 551 (2.6)                                285 (1.3)                    

^\*^Chi-square test for comparing the incidence between patients with and without disease history. VTE, Venous thromboembolism; DVT, Deep vein thrombosis; PE, Pulmonary embolism.

###### Incidence of VTE after knee replacement in patients with significant risk factors

![](jkms-31-80-i005)

  Risk factors            VTE           DVT              PE                                                                               
  ----------------------- ------------- ---------------- ---------- ------------- --------------- ---------- ----------- ---------------- ----------
  VTE history                                                                                                                             
   Yes (n = 644)          241 (17.2)    8.5 (7.2-10.1)   \< 0.001   199 (14.2)    7.5 (6.3-9.0)   \< 0.001   57 (4.1)    8.6 (6.3-11.6)   \< 0.001
   No (n = 26,661)        1,749 (3.4)                               1,500 (2.9)                              298 (0.6)                    
  Chronic heart failure                                                                                                                   
   Yes (n = 2,003)        182 (4.8)     1.3 (1.1-1.5)    0.001      132 (3.5)     1.1 (0.9-1.3)   0.479      62 (1.6)    2.7 (2.0-3.6)    \< 0.001
   No (n = 25,302)        1,808 (3.7)                               1,567 (3.2)                              293 (0.6)                    
  Arrhythmia                                                                                                                              
   Yes (n = 1,862)        206 (5.5)     1.7 (1.4-1.9)    \< 0.001   172 (4.6)     1.6 (1.3-1.9)   \< 0.001   45 (1.2)    2.0 (1.4-2.8)    \< 0.001
   No (n = 25,443)        1,784 (3.6)                               1,527 (3.1)                              310 (0.6)                    
  Atrial fibllation                                                                                                                       
   Yes (n = 736)          101 (6.8)     2.1 (1.7-2.6)    \< 0.001   78 (5.2)      1.8 (1.4-2.3)   \< 0.001   29 (2.0)    3.3 (2.2-4.9)    \< 0.001
   No (n = 26,569)        1,889 (3.7)                               1,621 (3.2)                              326 (0.6)                    

^\*^Chi-square test for comparing the incidence between patients with and without disease history. VTE, Venous thromboembolism; DVT, Deep vein thrombosis; PE, Pulmonary embolism.
